Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0028-3886.344668 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of pediatric patients with suspected allergies to COVID-19 vaccines.
J Allergy Clin Immunol Glob
February 2025
Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, Hong Kong, China.
Background: Adverse effects following immunizations (AEFIs) can contribute to vaccine hesitancy.
Objective: We evaluated clinical outcomes of AEFIs subsequent to administration of the coronavirus disease 2019 (COVID-19) vaccine at 2 pediatric allergy centers.
Methods: Data on pediatric patients referred for COVID-19 AEFI concerns between March 2021 and October 2022 were reviewed.
Evaluation of a self-screening tool and patient alert cards to help patients identify and manage severe adverse drug reactions.
Int J Clin Pharm
January 2025
Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002, Thailand.
Background: Few studies have examined the use of self-screening tools and patient alert cards (PAC) for screening adverse drug reactions (ADRs).
Aim: To evaluate the benefits of self-screening tools and PAC for screening ADRs.
Method: A prospective study of outpatients was conducted at a tertiary care teaching hospital.
Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses.
Diabetol Metab Syndr
January 2025
Bahrain Defence Force Royal Medical Services, Riffa, Kingdom of Bahrain.
Background: Dipeptidyl peptidase-4 inhibitors (DPP-4is) and drugs interfering with the renin-angiotensin-aldosterone system (RAAS) are frequently co-prescribed in type 2 diabetes management. Both drug classes have been independently associated with angioedema, raising concerns about potential interaction risks. This study aimed to evaluate the safety signals and interaction patterns for angioedema associated with DPP-4is alone and in combination with RAAS-interfering drugs.
View Article and Find Full Text PDFThe dynamics of thrombolysis over time in acute immunologic reactions.
Sci Rep
January 2025
Department of Emergency Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Article Synopsis
- Allergic reactions and angioedema are significant conditions in emergency care, affecting patient management.
- A study evaluated maximum lysis (ML) using thromboelastometry in patients with immunologic reactions, measuring ML at admission and two hours later.
- Results showed that patients still experiencing symptoms after two hours had higher ML than those who were asymptomatic, indicating a potential link between symptom persistence and changes in ML.
A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).
Sci Rep
December 2024
Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and angioedema. Sacubitril/valsartan-associated ototoxicity is often underreported in clinical studies and real-world settings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!